Prostatic androgen repressed message-1 (PARM-1) may play a role in prostatic cell immortalisation. Cornet AM, Hanon E, Reiter ER, Bruyninx M, Nguyen VH, Hennuy BR, Hennen GP, Closset JL, Biochemistry and Laboratory of Endocrinology, Institute of Pathology B23, Avenue de l'Hopital 3, University of Liege, 4000 Liege, Belgium - Prostate 2003;56(3):220-230

Author： Bosland M.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.5, 2003-09, pp. : 417-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue

By Friedrich B.   Jung K.   Lein M.   Turk   Rudolph B.   Hampel G.   Schnorr D.   Loening S.A.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 138-144

Elsevier

Access to resources Recommend Favorite

Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue

By            

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2886-2894

Spandidos Publications

Access to resources Recommend Favorite

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA - Proc Natl Acad Sci USA 2003;100:1250-1255

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 411-412

Elsevier

Access to resources Recommend Favorite

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l'Universite, de Montreal, Hopital Notre-Dame, Montreal, Quebec, Canada - J Natl Cancer Inst 2002;94:1458-1468

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 408-408

Elsevier

Access to resources Recommend Favorite

Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines

By Dizeyi N.   Ph.D. L.K.   Bjartell A.   Wu H.   Gadaleanu V.   Hansson J.   Helboe L.   Abrahamsson P.-A.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 3, 2002-05 ,pp. : 91-98

Elsevier

Access to resources Recommend Favorite